Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pharma Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1119332C details a novel asymmetric hydrogenation route for azepine intermediates, offering cost-effective and scalable production for kinase inhibitors like Balanol.
Patent CN1265650A reveals a novel double-protection strategy for synthesizing 6-amino-3-azabicyclo[3.1.0]hexane derivatives, offering superior stereoselectivity and cost-effective routes for quinolone antibiotic manufacturing.
Patent CN102304095B details a novel 5-step synthesis for Sulfadoxine, eliminating toxic catalysts and improving purity for cost-effective pharmaceutical manufacturing.
Patent CN106755254B details a mild enzymatic route for lipoic acid sterol ester, offering high purity and yield for food and pharma applications.
Novel cobalt catalyst enables asymmetric hydroboration of mixed olefins. Delivers high enantioselectivity and substantial cost reduction in pharmaceutical intermediates manufacturing.
Patent CN113200948A reveals a cost-effective copper-catalyzed route for chiral phthalides, offering high enantioselectivity and supply chain advantages for pharmaceutical manufacturers.
Patent CN1106395C details a novel asymmetric synthesis for IBAT inhibitor intermediates, offering superior stereocontrol and scalable manufacturing for pharmaceutical supply chains.
Patent CN106701698A reveals high-efficiency enzymatic synthesis for chiral alcohols. Offers cost reduction and high purity for pharmaceutical supply chains.
Patent CN108546691A details a novel 7β-HSDH mutant using NADH for cost-effective ursodeoxycholic acid production with high purity and yield.
Patent CN106995374A reveals catalyst-free oxygen oxidation for nitroaromatic acids. Delivers high purity, cost reduction, and scalable supply chain solutions.
Patent CN107814824A reveals a noble-metal-free route for steroid intermediates. This ensures high purity and supply chain stability for global pharmaceutical manufacturing partners.
Patent CN87100031A reveals microbial hydrolysis for high-purity S-Naproxen. Enables cost reduction in pharmaceutical intermediate manufacturing and supply chain reliability.
Novel hydrogenation method for 2-clopentylamino ethanol ensures high purity and cost efficiency. Ideal for reliable fine chemical intermediate supplier partnerships.
Patent CN102993224A reveals a novel synthesis for high-purity organic boron difluoride complexes, offering significant cost reduction in fluorescent material manufacturing.
Novel Strecker reaction route for Clopidogrel bisulfate. High yield, scalable process for pharmaceutical intermediates manufacturing.
Patent CN101675020A details a novel asymmetric hydrogenation method for high-purity optically active aldehydes like citronellal, offering enhanced catalyst stability and supply chain reliability.
Patent CN108358847B reveals a metal-free route for imidazolin-2-one compounds. This method offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN1399632A details a safer route for pyrimidine derivatives, eliminating hazardous Curtius rearrangement for reliable pharmaceutical intermediate supply.
Patent CN119119036A reveals catalyst-free pyridinium synthesis. Offers cost reduction in pharmaceutical manufacturing and high-purity intermediate supply chain reliability.
Novel PTC-catalyzed oxidation of 3,5-lutidine yields high-purity 5-methylnicotinic acid. Reduces water usage and boosts efficiency for Rupatadine manufacturing.